Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

  • 01:03

    Allogeneic Transplants for Multiple Myeloma with Dr. Bensinger

    in Health

    March is Myeloma Awareness month and we are exploring the allo transplant therapy route for myeloma patients in our talk with Dr. Bensinger. Why are allogeneic stem cell transplants risky for multiple myeloma patients? When does possible benefit outweigh the risks? RSVP to participate by asking a myeloma question LIVE on the talk to our panel of experts and patients. To mark the Myeloma month of awareness, we have extended our show time by 15 mins where we will have Sarah Kaufmann-Fink of MMore joining us to talk about MMores new research and crowdfunding venture.

  • 00:52

    Multiple Myeloma Update & Clinical Trials

    in Health

    This show is part of the Leukemia & Lymphoma Society Patient Education Series. 


    Our special guest is Dr. Christopher Yasenchak from Compass Oncology in Portland, Oregon. Dr. Yasenchak received his M.D. from Pennsylvania State University. He continued his training at the Mayo Clinic College of Medicine and is board certified in hematology, medical oncology and internal medicine.  His clinical focus is multiple myeloma, lymphoma, stem cell transplantation, gastrointestinal malignancies and clinical trials.

  • 00:52

    Multiple Myeloma Update & Clinical Trials

    in Health

    This show is part of the Leukemia & Lymphoma Society Patient Education Series.  Our special guest is Dr. Christopher Yasenchak from Compass Oncology in Portland, Oregon. Dr. Yasenchak received his M.D.  from Pennsylvania State University. He continued his training at the Mayo Clinic College of Medicine and is board certified in hematology, medical oncology and internal medicine.  His clinical focus is multiple myeloma, lymphoma, stem cell transplantation, gastrointestinal malignancies and clinical trials.  

  • 01:01

    Multiple Myeloma Diagnostic Tests - Types and Frequency w/ Dr. Joseph Mikhael

    in Health

    Myeloma presents itself with different features in each patient. In order to understand your disease and monitor it, you need to know which are the tests available and how often you have to get the tests done. No single test or study is adequate to tell the whole story about a patient's status, but when used together, test results can give a complete picture. Our experienced myeloma panel is talking to Dr. Joseph Mikhael about understanding your myeloma, types of diagnostic tests and their frequency.  


    Dr. Joseph Mikhael is a hematologist/oncologist at the Mayo Clinic in Arizona where he researches, teaches and treats multiple myeloma and related conditions. After completing medical school and residency at the University of Ottawa, he completed a second residency and fellowship at the University of Toronto and the Princess Margaret Hospital in Toronto, Ontario. At the Mayo Clinic, Dr. Mikhael is a principal investigator for clinical trials in both relapsed/refractory and newly diagnosed multiple myeloma.

  • 01:03

    Myeloma Crowd Radio: Dr. James Berenson, MD, IMBCR

    in Health

    Multiple myeloma is typically tracked by measuring the M-protein, also called the "M-spike." But in some patients, the M-protein gets lost, making it difficult if not impossible to detect myeloma levels without a bone marrow biopsy. Dr. James R. Berenson, MD of the Institute for Myeloma & Bone Cancer Research has been working on a new test (assay) and has found direct correllations between levels of BCMA and the M-spike. He also has identified new clues that BCMA levels can provide related to outcomes within specific patient populations. Learn more in this show about a new and potentially easier way to detect myeloma, which would be incredibly valuable for the non-secretor. 


    Special thanks to our episode sponsor, Takeda Oncology.

  • 01:20

    Myeloma Crowd Radio: Dr. Don Benson, MD, PhD, Ohio State University

    in Health

    Dr. Don Benson, MD, PhD of The James Cancer Center at Ohio State University is a multiple myeloma specialist with deep expertise in immunotherapy. He shares the growing and exciting world of immunotherapies in multiple myeloma - how they work and how they are opening up an exciting new set of opportunities for myeloma patients.

  • 01:25

    Myeloma Crowd Radio: Dr. Kenneth Anderson, MD, PhD, Dana-Farber Cancer Institute

    in Health

    The advances found for multiple myeloma over the past two decades have been extroardinary. Much has been learned, and much has been accomplished with new treatment developments and arguably more discoveries than other cancers in the same time period. The past is impressive for this complex cancer, but there is more work to do. Dr. Ken Anderson helped lead the way for the discovery of new developments over a prestigious career of 40 years. He shares with us a brief look back and what he sees for the road ahead towards a cure.


    Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at John’s Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome. 


    Thanks to our episode sponsor, Takeda Oncology

  • 01:10

    High Risk Multiple Myeloma Prognosis with Dr. Sagar Lonial

    in Health

    We are talking about high-risk multiple myeloma and its prognosis with Dr. Sagar Lonial this August. Make sure REGISTER in advance to ask Dr. Lonial your myeloma question. 


    Dr. Lonial is Professor at the Winship Cancer Institute of Emory University, Director of Translational Research, B-cell malignancy program as well as Associate Director of Hematology Oncology Fellowship Program. He staffs and works both on the transplant service as well as in the B-cell malignancy clinic. Dr. Lonial completed his Hematology-Oncology training at Emory University, and prior to that received his internal medicine residency at the Baylor College of Medicine in Houston Texas. There he spent an additional year as a Chief Medical Resident at the Ben Taub General Hospital as well as the Texas Heart Institute and St Lukes Hospital. Dr. Lonial is on the editorial board for Clinical Lymphoma and Myeloma and The American Journal of Clinical Oncology, as well as an ad hoc reviewer for Blood, Cancer Research, Clinical Cancer Research, Haematologica, and other journals. He has authored or co-authored over 40 papers and abstracts, and was recently appointed to Vice-chair for the ECOG myeloma committee.


     

  • 01:20

    Myeloma Crowd Radio: Dr. Ola Landgren, MD, PhD, Memorial Sloan Kettering

    in Health

    New developments for multiple myeloma are happening at an ever increasing pace. Dr. Ola Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center and heavily involved in the direction of myeloma research, both nationally and internationally. In this show he will give a wrap up of the recent Rome International Myeloma Working Group meeting as well as an ASH preview (for the upcoming December conference). He will also share up and coming clinical trials at Memorial Sloan Kettering Cancer Center to incorporate these new treatments into clinical practice. Learn what new drugs will be available and how they can be used in the myeloma clinic. 

  • 00:30
  • 01:06

    Myeloma Crowd Radio: Dr. Tomer Mark, MD, MSc, Weill Cornell Medical Center

    in Health

    Treatment for multiple myeloma is all about the combinations. Recently we've been hearing about the "BIRD" combinations. What are they and how effective are they? Learn from Dr. Tomer Mark, MD, MSc from Weill Cornell Medical Center about this new combination and what it means for myeloma patients.